Aerosol salmeterol fluticasone tiotropium United severefor very severe COPD patients to improve pulmonary function and quality of life.docVIP

 PAGE \* MERGEFORMAT 8 Aerosol salmeterol fluticasone tiotropium United severefor very severe COPD patients to improve pulmonary function and quality of life [Keywords:] Chronic obstructive pulmonary disease; Seretide; tiotropium; heavy; very severe; pulmonary function; quality of life This study focused on aerosol salmeterol fluticasone (Seretide) combined tiotropium extremely severe with severe chronic obstructive pulmonary disease (COPD) patients to improve pulmonary function and quality of life in order for future clinical work reference. 1 Materials and Methods 1.1 General information on selected cases were hospital January to September 2009 were treated with severe very severe COPD patients with 50 patients, 31 males and 19 females; are in line with 2002, the Chinese Medical Association Respiratory Diseases Branch of COPD Treatment Guidelines (1); age of 41 to 71 years (mean 54.6 + -7.2 years); severe (1 second forced expiratory volume (FEV1) / forced expiratory vital capacity (FVC) lt;70%, 30% FEV1 percentage of predicted value% “50% with or without chronic cough, sputum symptoms) in 35 cases, very severe (FEV1/FVC lt;70%, FEV1 lt;30% predicted value, associated with chronic respiratory failure) in 15 cases. to all patients were randomly divided into two groups and the control groups of 25 patients, two groups of general information was no significant difference (Pgt; 0.05), comparable. Methods All patients were given 1.2 oxygen, antibiotics, cough and phlegm and asthma and other basic medical treatment. Control morning and evening application Seretide (50 g salmeterol and fluticasone propionate 250 g) inhalation, the 1st. observation group were treated with Seretide United tiotropium therapy, every morning, dry powder inhaled tiotropium capsule 1 (18 g), and in the morning and evening, the 1st absorption Ru Shuli Diego. treatment time for 1 month. OUTCOME MEASURES 1.3 1 month after treatment lung function of two groups of patients, qu